Prevalence of novel candidate sjogren syndrome autoantibodies in the dry eye assessment and management (DREAM) study

Vatinee Y. Bunya, Gui Shuang Ying, Maureen G. Maguire, Eric Kuklinski, Meng C. Lin, Ellen Peskin, Penny Asbell

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To evaluate the prevalence of novel candidate Sjogren syndrome (SS) autoantibodies [salivary protein-1 (SP-1), parotid secretory protein, carbonic anhydrase 6] in the DRy Eye Assessment and Management (DREAM) cohort, a study evaluating the effectiveness of omega-3 fatty acid supplements for the treatment of dry eye. Methods: Participants underwent ocular surface examinations and serological testing for traditional and novel SS autoantibodies. Dry eye assessment and management participants were categorized into the following 3 groups: 1) no history of SS or other autoimmune diseases and negative traditional SS autoantibodies (n = 352); 2) no history of SS but a history of other autoimmune diseases (n = 66); and 3) those who met the 2012 American College of Rheumatology SS classification criteria (n = 52). Results: Eleven percent had a history of SS, and 6% of those without a history of SS most likely had undiagnosed SS. The SS group had a higher prevalence of SP-1 autoantibodies than the group without SS or other autoimmune diseases (33% vs. 19%; P = 0.02) but had no difference in carbonic anhydrase 6 (P = 0.31) or parotid secretory protein autoantibodies (P = 0.33). Participants who were positive for the traditional autoantibodies alone or positive for both traditional and novel autoantibodies had the highest scores for corneal (P = 0.002) and conjunctival staining (P, 0.001). Conclusions: Data from this multicenter, prospective study demonstrated that one of the novel candidate autoantibodies, SP-1, is associated with underlying SS and that novel autoantibodies may be associated with worse ocular surface disease. Future longitudinal studies are needed to evaluate their utility in screening patients with dry eye for SS.

Original languageEnglish (US)
Pages (from-to)1425-1430
Number of pages6
JournalCornea
Volume37
Issue number11
DOIs
StatePublished - Jan 1 2018

Fingerprint

Sjogren's Syndrome
Autoantibodies
Salivary Proteins and Peptides
Autoimmune Diseases
Dry Eye Syndromes
Eye Diseases
Omega-3 Fatty Acids
Multicenter Studies
Longitudinal Studies
Proteins
Cohort Studies

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Prevalence of novel candidate sjogren syndrome autoantibodies in the dry eye assessment and management (DREAM) study. / Bunya, Vatinee Y.; Ying, Gui Shuang; Maguire, Maureen G.; Kuklinski, Eric; Lin, Meng C.; Peskin, Ellen; Asbell, Penny.

In: Cornea, Vol. 37, No. 11, 01.01.2018, p. 1425-1430.

Research output: Contribution to journalArticle

Bunya, Vatinee Y. ; Ying, Gui Shuang ; Maguire, Maureen G. ; Kuklinski, Eric ; Lin, Meng C. ; Peskin, Ellen ; Asbell, Penny. / Prevalence of novel candidate sjogren syndrome autoantibodies in the dry eye assessment and management (DREAM) study. In: Cornea. 2018 ; Vol. 37, No. 11. pp. 1425-1430.
@article{54da1ef2f5f047ab911843aff8d5ae7a,
title = "Prevalence of novel candidate sjogren syndrome autoantibodies in the dry eye assessment and management (DREAM) study",
abstract = "Purpose: To evaluate the prevalence of novel candidate Sjogren syndrome (SS) autoantibodies [salivary protein-1 (SP-1), parotid secretory protein, carbonic anhydrase 6] in the DRy Eye Assessment and Management (DREAM) cohort, a study evaluating the effectiveness of omega-3 fatty acid supplements for the treatment of dry eye. Methods: Participants underwent ocular surface examinations and serological testing for traditional and novel SS autoantibodies. Dry eye assessment and management participants were categorized into the following 3 groups: 1) no history of SS or other autoimmune diseases and negative traditional SS autoantibodies (n = 352); 2) no history of SS but a history of other autoimmune diseases (n = 66); and 3) those who met the 2012 American College of Rheumatology SS classification criteria (n = 52). Results: Eleven percent had a history of SS, and 6{\%} of those without a history of SS most likely had undiagnosed SS. The SS group had a higher prevalence of SP-1 autoantibodies than the group without SS or other autoimmune diseases (33{\%} vs. 19{\%}; P = 0.02) but had no difference in carbonic anhydrase 6 (P = 0.31) or parotid secretory protein autoantibodies (P = 0.33). Participants who were positive for the traditional autoantibodies alone or positive for both traditional and novel autoantibodies had the highest scores for corneal (P = 0.002) and conjunctival staining (P, 0.001). Conclusions: Data from this multicenter, prospective study demonstrated that one of the novel candidate autoantibodies, SP-1, is associated with underlying SS and that novel autoantibodies may be associated with worse ocular surface disease. Future longitudinal studies are needed to evaluate their utility in screening patients with dry eye for SS.",
author = "Bunya, {Vatinee Y.} and Ying, {Gui Shuang} and Maguire, {Maureen G.} and Eric Kuklinski and Lin, {Meng C.} and Ellen Peskin and Penny Asbell",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/ICO.0000000000001714",
language = "English (US)",
volume = "37",
pages = "1425--1430",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Prevalence of novel candidate sjogren syndrome autoantibodies in the dry eye assessment and management (DREAM) study

AU - Bunya, Vatinee Y.

AU - Ying, Gui Shuang

AU - Maguire, Maureen G.

AU - Kuklinski, Eric

AU - Lin, Meng C.

AU - Peskin, Ellen

AU - Asbell, Penny

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: To evaluate the prevalence of novel candidate Sjogren syndrome (SS) autoantibodies [salivary protein-1 (SP-1), parotid secretory protein, carbonic anhydrase 6] in the DRy Eye Assessment and Management (DREAM) cohort, a study evaluating the effectiveness of omega-3 fatty acid supplements for the treatment of dry eye. Methods: Participants underwent ocular surface examinations and serological testing for traditional and novel SS autoantibodies. Dry eye assessment and management participants were categorized into the following 3 groups: 1) no history of SS or other autoimmune diseases and negative traditional SS autoantibodies (n = 352); 2) no history of SS but a history of other autoimmune diseases (n = 66); and 3) those who met the 2012 American College of Rheumatology SS classification criteria (n = 52). Results: Eleven percent had a history of SS, and 6% of those without a history of SS most likely had undiagnosed SS. The SS group had a higher prevalence of SP-1 autoantibodies than the group without SS or other autoimmune diseases (33% vs. 19%; P = 0.02) but had no difference in carbonic anhydrase 6 (P = 0.31) or parotid secretory protein autoantibodies (P = 0.33). Participants who were positive for the traditional autoantibodies alone or positive for both traditional and novel autoantibodies had the highest scores for corneal (P = 0.002) and conjunctival staining (P, 0.001). Conclusions: Data from this multicenter, prospective study demonstrated that one of the novel candidate autoantibodies, SP-1, is associated with underlying SS and that novel autoantibodies may be associated with worse ocular surface disease. Future longitudinal studies are needed to evaluate their utility in screening patients with dry eye for SS.

AB - Purpose: To evaluate the prevalence of novel candidate Sjogren syndrome (SS) autoantibodies [salivary protein-1 (SP-1), parotid secretory protein, carbonic anhydrase 6] in the DRy Eye Assessment and Management (DREAM) cohort, a study evaluating the effectiveness of omega-3 fatty acid supplements for the treatment of dry eye. Methods: Participants underwent ocular surface examinations and serological testing for traditional and novel SS autoantibodies. Dry eye assessment and management participants were categorized into the following 3 groups: 1) no history of SS or other autoimmune diseases and negative traditional SS autoantibodies (n = 352); 2) no history of SS but a history of other autoimmune diseases (n = 66); and 3) those who met the 2012 American College of Rheumatology SS classification criteria (n = 52). Results: Eleven percent had a history of SS, and 6% of those without a history of SS most likely had undiagnosed SS. The SS group had a higher prevalence of SP-1 autoantibodies than the group without SS or other autoimmune diseases (33% vs. 19%; P = 0.02) but had no difference in carbonic anhydrase 6 (P = 0.31) or parotid secretory protein autoantibodies (P = 0.33). Participants who were positive for the traditional autoantibodies alone or positive for both traditional and novel autoantibodies had the highest scores for corneal (P = 0.002) and conjunctival staining (P, 0.001). Conclusions: Data from this multicenter, prospective study demonstrated that one of the novel candidate autoantibodies, SP-1, is associated with underlying SS and that novel autoantibodies may be associated with worse ocular surface disease. Future longitudinal studies are needed to evaluate their utility in screening patients with dry eye for SS.

UR - http://www.scopus.com/inward/record.url?scp=85054428527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054428527&partnerID=8YFLogxK

U2 - 10.1097/ICO.0000000000001714

DO - 10.1097/ICO.0000000000001714

M3 - Article

VL - 37

SP - 1425

EP - 1430

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 11

ER -